Joint Formulary & PAD

Azilsartan medoxomil - Hypertension

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Azilsartan medoxomil
Indication :
Hypertension
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Azilsartan medoxomil is used to treat.

  • No records returned.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the 1st line use of Angiotensin Receptor Blockers (ARBs) instead of an Angiotensin Converting Enzyme (ACE) inhibitor, for adults with hypertension where the use of an ARB or ACE is deemed equally appropriate.

Eprosartan and Azlisartan are not one of the locally preferred ARBs. See below

Losartan or candesartan - 1st line

Alternative options:
Irebsartan - Green
Telmisartan - Green
Valsartan - Green
Olmesartan - Green

Azlisartan - do not initiate in new patients
Eprosartan - do not initiate in new patients

Local hypertension guidelines / pathways will be reviewed and updated in light of this decision